Treatment of Demodex Blepharitis

EP: 1.Overview of Demodex Blepharitis

EP: 2.Pathophysiology of Demodex Blepharitis

EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice

EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis

EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis

Now Viewing

EP: 6.Treatment of Demodex Blepharitis

EP: 7.Diagnosis and Prevalence of Demodex Blepharitis

EP: 8.Exploring a Recently Approved Therapy for Demodex

EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis

EP: 10.Outlook on the Future of Demodex Blepharitis Treatment

EP: 11.Understanding Demodex Blepharitis Pathogenesis

EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment

EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment

This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD.

Yeu discusses how the recent FDA approval of lotilaner ophthalmic solution 0.25% (Xdemvy) finally provides an effective treatment for patients with Demodex blepharitis. Unlike past therapies, this clear solution dosed twice daily has superb efficacy alongside excellent safety and tolerability. In two combined studies, 50% of patients had a reduction of collarettes and 60% of patients had mites completely eradicated. Such substantial improvement was unprecedented. Additionally, the solution form is preferable to a blurring ointment that is hard to apply. Yeu is excited to have an excellent therapeutic option now. She can educate and empower patients about this new treatment, targeting the root cause of their condition.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.